Patents Assigned to Biogen MA Inc.
  • Methods and compositions for inactivating enveloped viruses
    Patent number: 10188732
    Abstract: Aspects of the invention provide therapeutic recombinant protein preparations and methods of preparing therapeutic recombinant protein, which methods include contacting recombinant protein preparations with zwitterionic detergent at or above critical micelle concentration of the detergent.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: January 29, 2019
    Assignee: Biogen MA Inc.
    Inventors: Lynn Edward Conley, Yinying Tao
  • Methods of Treating Multiple Sclerosis
    Publication number: 20190008817
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Application
    Filed: July 24, 2018
    Publication date: January 10, 2019
    Applicant: Biogen MA Inc.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • Controlled Release Dosage Form for Once Daily Administration of Dimethyl Fumarate
    Publication number: 20190008768
    Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.
    Type: Application
    Filed: September 14, 2018
    Publication date: January 10, 2019
    Applicant: Biogen MA Inc.
    Inventors: Peter Zawaneh, Shyam B. Karki, Michael Kaufman, Cheuk-Yui Leung, Jinquan Dong, Ernest Quan, Kalyan Vasudevan
  • Controlled release dosage form for once daily administration of dimethyl fumarate
    Patent number: 10172794
    Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: January 8, 2019
    Assignee: Biogen MA Inc.
    Inventors: Peter Zawaneh, Shyam B. Karki, Michael Kaufman, Cheuk-Yui Leung, Jinquan Dong, Ernest Quan, Kalyan Vasudevan
  • Bicyclic aryl sphingosine 1-phosphate analogs
    Patent number: 10166250
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: January 1, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
  • ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIES AND USES THEREOF
    Publication number: 20180362652
    Abstract: Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
    Type: Application
    Filed: January 12, 2018
    Publication date: December 20, 2018
    Applicant: Biogen MA Inc.
    Inventors: Justin A. Caravella, Ellen A. Garber Stark, Dania Mounir Rabah, Frederick R. Taylor
  • Rapid generation of anti-idiotypic antibodies
    Patent number: 10150817
    Abstract: The present disclosure relates to in vivo methods for producing anti-idiotypic antibodies. In some aspects, anti-idiotypic antibodies are generated by co-administering to a mouse a first antibody having a murine IgG2a isotype and a second antibody that targets mouse B cells and has a murine IgG2a isotype. In some embodiments, the mouse expresses the Igh-1b allele of IgG2a, and the second antibody binds a mouse B cell surface marker selected from the group consisting of CD19, CD20, CD21, CD22, CD40, CD45, IgM, and IgD.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: December 11, 2018
    Assignee: Biogen MA Inc.
    Inventors: Robert J. Dunn, Marilyn R. Kehry
  • ATX modulating agents
    Patent number: 10144732
    Abstract: Compounds of formula (I) can modulate the activity of autotaxin (ATX).
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: December 4, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Gnanasambandam Kumaravel, Hairuo Peng, Zhili Xin
  • CONJUGATION METHODS FOR MODIFYING OR IMMOBILIZING PROTEINS
    Publication number: 20180319838
    Abstract: The present disclosure relates, in some aspects, to protein-ligand localized conjugation technology with respect to immobilized functional proteins for affinity enrichment and/or modified proteins for therapeutic applications.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 8, 2018
    Applicant: Biogen MA Inc.
    Inventors: Carl CO, John E. COUGHLIN
  • Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
    Patent number: 10119979
    Abstract: Methods and compositions for treating stroke are disclosed.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: November 6, 2018
    Assignee: Biogen MA Inc.
    Inventors: Jane K. Relton, Humphrey Gardner
  • Method of assessing risk of PML
    Patent number: 10119976
    Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: November 6, 2018
    Assignee: Biogen MA Inc.
    Inventors: Gary Lewis Bloomgren, Carmen Bozic, Sophia Lee, Amy Pace, Tatiana Plavina, Meena Subramanyam
  • Trapping reagents for reactive metabolites screening
    Patent number: 10100081
    Abstract: The present invention provides compounds of Formula (I) and (II): wherein R1, R2, R4, R5, R6, X and n are as defined herein, and wherein R3 is hydrogen or a sulfur protecting group. Compounds of Formula (I) and (II), wherein R3 is hydrogen, may be useful in methods for detecting a reactive metabolite in a sample, e.g., wherein the metabolite is generated from the metabolism of a test compound, and wherein the metabolite and the compound of Formula (I) or (II) react to form a detectable adduct, e.g., detectable by mass spectrometry.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: October 16, 2018
    Assignee: Biogen MA Inc.
    Inventor: Natalia Penner
  • COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
    Publication number: 20180291376
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Application
    Filed: November 20, 2017
    Publication date: October 11, 2018
    Applicants: Biogen MA Inc., Cold Spring Harbor Laboratory
    Inventors: Brenda F. Baker, Adrian R. Krainer, Yimin Hua
  • Methods and Compositions for the Intravenous Administration of Fumarates for the Treatment of Neurological Diseases
    Publication number: 20180289655
    Abstract: Disclosed herein are methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases, such as stroke, amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, Parkinson's disease, and Multiple Sclerosis.
    Type: Application
    Filed: March 18, 2016
    Publication date: October 11, 2018
    Applicant: Biogen MA Inc.
    Inventors: Ajay Verma, Robert Scannevin, Shyam Karki, Fengmei Zheng
  • CELL CULTURE METHODS AND SYSTEMS
    Publication number: 20180291329
    Abstract: The present disclosure relates, in some aspects, to the field of process analytical technology with respect to biotherapeutic protein production processes and products.
    Type: Application
    Filed: May 27, 2016
    Publication date: October 11, 2018
    Applicant: Biogen MA Inc.
    Inventors: Justin Moretto, Thomas Matthews, Brandon Moore, Terrence Dobrowsky, An Zhang, John Smelko, Brandon Berry, Kelly Wiltberger
  • METHODS OF MODULATING IMMUNE RESPONSES USING BCMA POLYPEPTIDE
    Publication number: 20180273605
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Application
    Filed: May 15, 2017
    Publication date: September 27, 2018
    Applicants: Biogen MA Inc., Topotarget Switzerland SA
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Neuroprotection in Demyelinating Diseases
    Publication number: 20180271821
    Abstract: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Applicant: Biogen MA Inc.
    Inventor: Ralf Gold
  • Heterobicyclic sphingosine 1-phosphate analogs
    Patent number: 10081646
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: September 25, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Wen-Cherng Lee, Edward Yin-Shiang Lin, Xiaogao Liu, Bin Ma, Daniel M. Scott, Zhan Shi, Jermaine Thomas, Arthur G. Taveras, Guo Zhu Zheng
  • Biaryl inhibitors of bruton's tyrosine kinase
    Patent number: 10081619
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 25, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Lihong Sun, Lei Zhang, Gnanasambandam Kumaravel, Joseph P. Lyssikatos, Kevin Koch, Hua Miao
  • PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
    Publication number: 20180263946
    Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Applicant: Biogen MA Inc.
    Inventors: David Goldman, Katherine Dawson, Ajay Nirula